Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer Weighs Options For Future Of Established Products Business Unit As Revenues Show Strong Trends: Emerging Markets Earnings Roundup (Part 3)

This article was originally published in PharmAsia News

Executive Summary

Emerging markets remained a key focus of Big Pharma during first quarter earnings calls, with many highlighting exceptional growth in these markets, particularly China. Perhaps the most interesting Q call of all was Pfizer Inc., which discussed in more detail whether it plans to spin out its emerging markets unit.
Advertisement

Related Content

Sale Of Pfizer’s Established Products Not Off The Table, Exec Says
Hot Opportunities In The African Emerging Markets - A Look At South Africa (Part 1 of 2)
Hot Opportunities In The African Emerging Markets - A Look At South Africa (Part 1 of 2)
Pfizer Looks To Ramp Up Branded Generics Via MOU With China's Hisun
Pfizer Looks To Ramp Up Branded Generics Via MOU With China's Hisun
Merck Looks To Leverage "Next 10" For Growth: Emerging Markets Earnings Roundup (Part 4)
BMS Benefits From Focused Strategy, Novartis Looks To Vaccines; Abbott Tries To Educate U.S. Investors: Emerging Markets Earnings Roundup (Part 2)
BMS Benefits From Focused Strategy, Novartis Looks To Vaccines; Abbott Tries To Educate U.S. Investors: Emerging Markets Earnings Roundup (Part 2)
Abbott, Eli Lilly, Novartis: Emerging Markets Earnings Round Up (Part 1)
AstraZeneca, Pfizer, GlaxoSmithKline: Emerging Markets Earnings Roundup (Part 2 of 2)
Advertisement
UsernamePublicRestriction

Register

SC078151

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel